The North America Rabeprazole Sodium Market is projected to witness market growth of 3.1% CAGR during the forecast period (2024-2031).
The US market dominated the North America Rabeprazole Sodium Market by Country in 2023, and is forecast to continue being a dominant market till 2031; thereby, achieving a market value of $233.90 millions by 2031. The Canada market is experiencing a CAGR of 5.3% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 4.4% during (2024 - 2031).
Rabeprazole sodium is a proton pump inhibitor (PPI) medication that is predominantly indicated for the treatment of a variety of acid-related gastrointestinal disorders by reducing stomach acid production. PPI is a class of medications that function by permanently suppressing the enzyme system (the proton pump), which is responsible for the ultimate stage of acid production in the stomach lining.
Additionally, within the pharmaceutical industry, the market is a critical segment that is dedicated to the treatment of gastrointestinal disorders, with a particular emphasis on those that are associated with excessive gastric acid production.
In North America, the increasing demand for it is fueled by the rising prevalence of gastrointestinal disorders. According to the National Library of Medicine, the estimated prevalence of GERD in the US is between 18.1% and 27.8%. The prevalence of GERD is slightly higher in men than in women. This substantial patient base creates a significant market for effective treatments like rabeprazole sodium.
The US market dominated the North America Rabeprazole Sodium Market by Country in 2023, and is forecast to continue being a dominant market till 2031; thereby, achieving a market value of $233.90 millions by 2031. The Canada market is experiencing a CAGR of 5.3% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 4.4% during (2024 - 2031).
Rabeprazole sodium is a proton pump inhibitor (PPI) medication that is predominantly indicated for the treatment of a variety of acid-related gastrointestinal disorders by reducing stomach acid production. PPI is a class of medications that function by permanently suppressing the enzyme system (the proton pump), which is responsible for the ultimate stage of acid production in the stomach lining.
Additionally, within the pharmaceutical industry, the market is a critical segment that is dedicated to the treatment of gastrointestinal disorders, with a particular emphasis on those that are associated with excessive gastric acid production.
In North America, the increasing demand for it is fueled by the rising prevalence of gastrointestinal disorders. According to the National Library of Medicine, the estimated prevalence of GERD in the US is between 18.1% and 27.8%. The prevalence of GERD is slightly higher in men than in women. This substantial patient base creates a significant market for effective treatments like rabeprazole sodium.
List of Key Companies Profiled
- Cipla Limited
- Sun Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Reddy’s Laboratories Ltd.
- Cadila Pharmaceuticals Ltd
- Alembic Pharmaceuticals Ltd
- Woodward Pharma
- Elikem Pharmaceuticals Pvt Ltd
- Jasco Labs Private Limited
- Torrent Pharmaceuticals Ltd.
Market Report Segmentation
By Age- Below 55 years and
- Above 55 years
- Drug & Retail Store Pharmacies,
- Hospital Pharmacies and
- Online Pharmacies
- Gastroesophageal Reflux Disease,
- Peptic Ulcer and
- Others
- US
- Canada
- Mexico
- Rest of North America
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. North America Rabeprazole Sodium Market by Age
Chapter 5. North America Rabeprazole Sodium Market by Distribution Channel
Chapter 6. North America Rabeprazole Sodium Market by Application
Chapter 7. North America Rabeprazole Sodium Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Cipla Limited
- Sun Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Cadila Pharmaceuticals Ltd
- Alembic Pharmaceuticals Ltd
- Woodward Pharma
- Elikem Pharmaceuticals Pvt Ltd
- Jasco Labs Private Limited
- Torrent Pharmaceuticals Ltd.
Methodology
LOADING...